ABSTRACT
Background We studied the secondary attack rate (SAR), risk factors, and precautionary practices of household transmission in a prospective longitudinal study. Moreover, we compared household transmission between the Alpha (B.1.1.7) variant and non-variants of concern (non-VOCs).
Methods We recruited households of confirmed COVID-19 cases from May 2020 to May 2021. Households received 8 home visits over 6 weeks. Biological samples and questionnaire data were collected.
Results We recruited 70 confirmed COVID-19 cases and 146 household contacts. Transmission occurred in 60% of the households; the overall SAR for household contacts was 49.6%. The SAR was significantly higher for the Alpha variant (77.8%) compared with non-VOC variants (42.5%) and was associated with a higher viral load. SAR was higher in household contacts aged ≥40 years (64%) than in younger contacts (40-47%), and for contacts of cases with loss of taste/smell. Close contact prior to confirmation of infection tended to give a higher SAR. A significantly lower SAR was found for sleeping separately from the primary case after confirmation of infection.
Conclusion We found substantial household transmission, particularly for the Alpha variant. Precautionary practices seem to reduce SAR; however, prevention of transmission within households may become difficult with more transmissible variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Norwegian Institute of Public health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Committee for Medical and Health Research Ethics (REC), South East Norway B (approval no. 118354). A data protection impact assessment (DPIA) for the study was approved by the data protection officer at the Norwegian Institute of Public Health (NIPH).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are not publicly available
